PDS Biotech licenses TARP from National Cancer Institute

By The Science Advisory Board staff writers

November 8, 2021 -- PDS Biotechnology has licensed the tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP) from the U.S. National Cancer Institute (NCI).

The worldwide nonexclusive license secures rights for the proprietary TARP antigen from the NCI with patent protection through 2034. TARP is used to treat myeloid leukemia and prostate and breast cancers.

PDS Biotech said it is exploring the effectiveness of its candidate PDS0102, which is made using PDS Biotechnology's Versamune T-cell-activating platform and TARP.

PDS Biotech to develop COVID-19 vaccine in Brazil
PDS Biotechnology announced it has received a $60 million commitment to begin clinical testing and commercialization of a second-generation COVID-19...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter